IVVD vs PFE

Invivyd (IVVD) presents a compelling high-risk, high-reward opportunity, demonstrating significant improvement since our last analysis. The reported Q4 2025 earnings (March 5, 2026) were a major catalyst, showcasing a substantial revenue beat ($17.2M actual vs. $15.77M est.), a 31% sequential growth for PEMGARDA, and a remarkable 110% YoY revenue increase for FY 2025 to $53.4M. Critically, Q4 2025...

Pfizer Inc. remains a mature, large-cap pharmaceutical company with no material changes since the last analysis that would indicate a path to 10x growth. The company faces ongoing headwinds from declining COVID product sales and patent cliffs. While a settlement extended Vyndamax exclusivity, this is insufficient to offset broader challenges. Upcoming Q1 2026 earnings are projected to show a ~20% ...